Wolverine Asset Management LLC Acquires 1,634 Shares of Insulet Co. (NASDAQ:PODD)

Wolverine Asset Management LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD) by 43.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,379 shares of the medical instruments supplier’s stock after purchasing an additional 1,634 shares during the quarter. Wolverine Asset Management LLC’s holdings in Insulet were worth $1,252,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. QRG Capital Management Inc. bought a new stake in shares of Insulet during the third quarter worth $297,000. Diversified Trust Co lifted its position in shares of Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after purchasing an additional 4,348 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of Insulet by 113.8% during the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after purchasing an additional 3,539 shares during the last quarter. Natixis purchased a new position in shares of Insulet during the first quarter valued at $3,610,000. Finally, Seven Eight Capital LP purchased a new position in shares of Insulet during the first quarter valued at $1,418,000.

Insulet Trading Down 0.2 %

Insulet stock opened at $275.10 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a 52 week low of $156.00 and a 52 week high of $279.40. The company has a market capitalization of $19.29 billion, a price-to-earnings ratio of 47.11, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22. The stock has a 50-day moving average price of $234.83 and a 200 day moving average price of $206.03.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Citigroup raised their price target on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. UBS Group lifted their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Canaccord Genuity Group lifted their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.